Latest News on OPRX

Financial News Based On Company


Advertisement
Advertisement

OptimizeRx to Participate in the 15th Annual ROTH Technology Conference

https://www.manilatimes.net/2026/11/16/tmt-newswire/globenewswire/optimizerx-to-participate-in-the-15th-annual-roth-technology-conference/2470844/amp
OptimizeRx Corp. (Nasdaq: OPRX), a healthcare technology solutions provider, announced its management will participate in the 15th Annual ROTH Technology Conference on November 18, 2026, in New York, NY. The company specializes in connecting life science brands with healthcare professionals and patients using AI-driven tools like the Dynamic Audience Activation Platform and Micro-Neighborhood® Targeting. OptimizeRx aims to deliver synchronized marketing solutions to improve treatment decisions and patient outcomes.

The ROTH Technology Conference's 15th annual event is set for New York, with OptimizeRx management taking part.

https://www.stocktitan.net/news/OPRX/optimize-rx-to-participate-in-the-15th-annual-roth-technology-yikr9lvxz4cx.html
OptimizeRx (Nasdaq: OPRX) announced that its management will participate in the 15th Annual ROTH Technology Conference on November 18, 2026, in New York, NY. The company, a leading provider of healthcare technology solutions, enables life sciences companies to engage with healthcare professionals and patients at crucial decision points. OptimizeRx focuses on redefining how life science brands connect with their audience through AI-driven tools and synchronized marketing solutions.

Form 8K OPTIMIZERx Corp For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-optimizerx-corp-for-13-november-93CH-4957798
OPTIMIZERx Corp (OPRX) filed a Form 8K on November 13, 2026, as reported by Investing.com. The stock experienced a -17.25% change following this announcement. The article provides the filing information and its immediate impact on the company's stock performance.

Form 8K OPTIMIZERx Corp For: 13 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-optimizerx-corp-for-13-november-93CH-2807210
This article from Investing.com reports on an 8K filing by OPTIMIZERx Corp for November 13, 2026. The brief piece indicates that the document is publicly available and relates to the company's financial activities. It also references the company's stock symbol, OPRX, and its current price performance.

OptimizeRx Q3 Revenue Falls 17% to $21.6 Million; Updates 2026 Outlook

https://www.tradingview.com/news/tradingview:805fb6004bf00:0-optimizerx-q3-revenue-falls-17-to-21-6-million-updates-2026-outlook/
OptimizeRx reported a 17% year-over-year decrease in Q3 2026 revenue, falling to $21.6 million, though GAAP net income and adjusted EBITDA both increased. The company updated its 2026 revenue guidance downwards to $87 million to $93 million but maintained its adjusted EBITDA outlook. Management highlighted expanding opportunities, renewed customer spending, and growth in 2027 contracted revenue, alongside strategic platform enhancements and partnerships.
Advertisement

Form 8K OPTIMIZERx Corp For: 13 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-optimizerx-corp-for-13-november-93CH-4981902
This article from Investing.com announces the filing of a Form 8K by OPTIMIZERx Corp on November 13, 2026. The filing is a standard regulatory disclosure for significant events that shareholders should know about. The article provides the title of the filing without further details about its content.

OptimizeRx Corporation Stock 12‑Month Price Target Cut to $12.1, Implies 35% Upside

https://www.tradingview.com/news/tradingview:d04ed94210021:0-optimizerx-corporation-stock-12-month-price-target-cut-to-12-1-implies-35-upside/
OptimizeRx Corporation's average 12-month price target has been reduced from $12.6 to $12.1 by analysts, with individual forecasts ranging from $10 to $18 per share. Based on the closing price on November 11, this new target suggests a potential upside of approximately 35%. The consensus rating from 6 covering analysts remains a "Buy," with no "Holds" or "Sells."

These Analysts Cut Their Forecasts On OptimizeRx After Q3 Results

https://www.benzinga.com/analyst-stock-ratings/price-target/26/11/63206448/these-analysts-cut-their-forecasts-on-optimizerx-after-q3-results
OptimizeRx Corporation reported strong Q3 earnings, beating analyst estimates for both earnings per share and sales. However, the company lowered its full-year 2026 sales guidance, leading to a significant dip in its share price and prompting analysts from Stifel and B. Riley Securities to reduce their price targets while maintaining Buy ratings.

OptimizeRx Corp (OPRX) (Q3 2026) Earnings Call Highlights: Margin Expansion and Programmatic ...

https://sg.finance.yahoo.com/news/optimizerx-corp-oprx-q3-2026-150447096.html
OptimizeRx Corp reported Q3 2026 revenue of $21.6 million and adjusted EBITDA of $6.3 million, exceeding expectations due to margin expansion and cost reductions. Despite a 17% year-over-year revenue decline and lowered full-year guidance, the company is advancing its programmatic strategy and seeing a returning top-five client. Management expects improved net revenue retention and strong 2027 contracted revenue, emphasizing debt repayment and potential share buybacks.

OptimizeRx Corp (OPRX) (Q3 2026) Earnings Call Highlights: Margin Expansion and Programmatic ...

https://uk.finance.yahoo.com/news/optimizerx-corp-oprx-q3-2026-150447096.html
OptimizeRx Corp reported Q3 2026 revenue of $21.6 million and adjusted EBITDA of $6.3 million, both exceeding expectations, with a significant expansion in adjusted EBITDA margin to 29%. Despite a 17% year-over-year revenue decline due to reduced spending from large customers, the company's programmatic strategy is advancing, and a top-five client has returned. Full-year revenue guidance was lowered, but management expects improvement in 2027, driven by programmatic growth and returning client spending.
Advertisement

OptimizeRx Shares Tumble 20% After-Hours: Here's Why

https://www.benzinga.com/markets/equities/26/11/63172223/optimizerx-shares-tumble-20-after-hours-heres-why
OptimizeRx Corp. (NASDAQ: OPRX) shares fell 20.11% in after-hours trading despite reporting third-quarter revenue and adjusted earnings that beat analyst estimates. The tumble was primarily driven by the company lowering its fiscal 2026 revenue guidance from $95 million to $100 million to a new range of $87 million to $93 million, citing lower in-year contracted revenue. Despite this, the company maintained its adjusted EBITDA outlook.

OPTIMIZERx earnings beat by $0.03, revenue topped estimates

https://www.investing.com/news/earnings/optimizerx-earnings-beat-by-003-revenue-topped-estimates-5020106
OPTIMIZERx (NASDAQ: OPRX) reported strong third-quarter results, beating analyst estimates with an EPS of $0.20, $0.03 higher than predicted, and revenue of $21.62M, surpassing the consensus of $21.55M. The company's stock, currently at $8.95, has seen a 2.64% increase in the last three months but a 42.11% decline over the past year. InvestingPro rates OPTIMIZERx's financial health as "great performance."

OptimizeRx Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63170518/optimizerx-q3-2026-earnings-call-transcript
OptimizeRx reported Q3 2026 revenue of $21.6 million and adjusted EBITDA of $6.3 million, exceeding consensus despite a 17% year-over-year revenue decline. The company updated its full-year 2026 revenue guidance to $87 million-$93 million due to delayed customer spending but maintained its adjusted EBITDA guidance. Strategic initiatives include strengthening programmatic partnerships and expanding its AI-enabled product portfolio, with promising signs for 2027 growth.

OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

https://www.manilatimes.net/2026/11/12/tmt-newswire/globenewswire/optimizerx-reports-third-quarter-2026-financial-results-and-updates-fiscal-year-2026-guidance/2467891
OptimizeRx Corp. announced its Q3 2026 financial results, with revenue totaling $21.6 million and adjusted EBITDA of $6.3 million, exceeding consensus expectations despite a year-over-year revenue decrease. The company updated its fiscal year 2026 revenue guidance to $87-$93 million while maintaining its adjusted EBITDA guidance of $21-$25 million. OptimizeRx highlighted its strategic focus on AI-enabled platforms, proprietary data, and an integrated EHR network to drive future growth and shareholder value.

Revenue fell 17% at OptimizeRx, which reported $1.2 million in profit.

https://www.stocktitan.net/news/OPRX/optimize-rx-reports-third-quarter-2026-financial-results-and-updates-5pc9yks6trd2.html
OptimizeRx (OPRX) reported a 17% year-over-year revenue decrease to $21.6 million in Q3 2026, lowering its full-year 2026 revenue guidance to $87 million to $93 million. Despite the revenue decline, GAAP net income rose to $1.2 million and adjusted EBITDA increased to $6.3 million, with adjusted EBITDA guidance remaining unchanged at $21 million to $25 million. The company noted that in-year contracted revenue is below prior-year levels but sees growth in contracted revenue for 2027 and renewed spending from a significant customer in Q4.
Advertisement

OptimizeRx Misses The Whisper As Margin Gains Run Into Another Revenue Guidance Cut

https://finviz.com/news/421331/optimizerx-misses-the-whisper-as-margin-gains-run-into-another-revenue-guidance-cut
OptimizeRx (NASDAQ: OPRX) reported Q3 non-GAAP earnings that beat consensus but missed the "Earnings Whisper" number, while revenue edged past consensus but fell year-over-year. The company showed improved profitability with expanded adjusted EBITDA margins, but revenue guidance was lowered again, indicating a shrinking top line. The market is now looking for strong Q4 execution and 2027 growth, driven by a returning top client and increased programmatic access, to validate the turnaround narrative.

OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

https://www.quantisnow.com/insight/optimizerx-reports-third-quarter-2026-financial-results-and-updates-fiscal-6785432
OptimizeRx announced its third-quarter 2026 financial results, reporting a 17% decrease in revenue to $21.6 million but a 23% increase in adjusted EBITDA to $6.3 million. The company updated its fiscal year 2026 revenue guidance, lowering it to $87 million to $93 million, while maintaining its adjusted EBITDA guidance. Shareholders may be concerned by the revenue decline, but the company has also reduced debt by $9.3 million.

OptimizeRx Rallied 38% On Margins; Now It Must Show Demand Has Stopped Shrinking

https://finviz.com/news/414941/optimizerx-rallied-38-on-margins-now-it-must-show-demand-has-stopped-shrinking
OptimizeRx's stock has surged 38% despite shrinking sales and two guidance cuts, driven by optimism around improving margins, a cleaner balance sheet, and a new programmatic channel. The upcoming third-quarter report will be crucial to validate this market bet, with investors looking for stabilization in demand indicators like net revenue retention and contracted revenue, alongside early proof points for new growth catalysts. The company needs to demonstrate that demand has bottomed and that revenue mix is shifting towards more durable, higher-margin dollars to sustain the rally.

OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 P.m. ET

https://www.moomoo.com/news/post/1002649004/optimizerx-sets-third-quarter-2026-conference-call-for-november-11
OptimizeRx (NASDAQ: OPRX) will host a conference call on November 11, 2026, at 4:30 P.m. ET to discuss its financial results for the third quarter of 2026. The company, a leading provider of digital health solutions, will also provide a business update during the call. Investors and interested parties can access the call via webcast or dial-in.

OptimizeRx Corporation (OPRX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/OPRX/seasonality/
This article from Yahoo Finance displays a seasonal returns chart for OptimizeRx Corporation (OPRX). It presents the average monthly price return for OPRX between 2016 and 2026, alongside current stock information and related market data. The article provides financial context without extensive analysis.
Advertisement

OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET

https://www.manilatimes.net/2026/10/28/tmt-newswire/globenewswire/optimizerx-sets-third-quarter-2026-conference-call-for-november-11-2026-at-430-pm-et/2456013/amp
OptimizeRx Corp. (Nasdaq: OPRX) has announced it will host a conference call on Wednesday, November 11, 2026, at 4:30 p.m. Eastern Time. The call is to discuss the company's financial results for the third quarter period ended September 30, 2026. Financial results will be released in a press release prior to the call, which will also include a question-and-answer session with management.

Third-quarter results will come before OptimizeRx’s Nov. 11 call.

https://www.stocktitan.net/news/OPRX/optimize-rx-sets-third-quarter-2026-conference-call-for-november-11-mbpgpf94uzoc.html
OptimizeRx (OPRX) has scheduled its third-quarter 2026 earnings conference call for November 11, 2026, at 4:30 p.m. ET. The company will release its financial results for the quarter ended September 30, 2026, in a press release prior to the call. Management will host the discussion, followed by a question-and-answer session.

OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET

https://finance.yahoo.com/healthcare/articles/optimizerx-sets-third-quarter-2026-113000601.html
OptimizeRx Corporation (Nasdaq: OPRX) has scheduled a conference call for Wednesday, November 11, 2026, at 4:30 p.m. Eastern Time to discuss its financial results for the third quarter ended September 30, 2026. The financial results will be released in a press release prior to the call. A replay of the call will be available for 12 months on the OptimizeRx website.

Citizens reiterates OptimizeRx stock rating citing digital spend expansion

https://www.investing.com/news/analyst-ratings/citizens-reiterates-optimizerx-stock-rating-citing-digital-spend-expansion-93CH-4974739
Citizens has reiterated a Market Outperform rating and $11.00 price target on OptimizeRx (NASDAQ:OPRX) despite modeling a year-over-year revenue decline for 2026 due to factors like a lack of managed services revenue and macroeconomic headwinds. The company is focusing on expanding into the demand-side platform (DSP) market to tap into approximately 80% of digital spend. OptimizeRx shows strong liquidity with a current ratio of 5.58 and appears undervalued according to InvestingPro analysis, with Citizens projecting $18 million in free cash flow for 2026.

Over 1 million provider IDs will be reachable as electronic-record ads join broader health campaigns.

https://www.stocktitan.net/news/OPRX/optimize-rx-and-pulse-point-partner-to-connect-hcp-media-across-the-gsv2dfga93rf.html
OptimizeRx has partnered with PulsePoint to integrate its electronic health record (EHR) and e-prescribing advertising inventory, making it available to PulsePoint clients. This collaboration will expand programmatic access to point-of-care advertising, allowing advertisers to incorporate these placements into existing automated media-buying workflows alongside other healthcare professional campaigns. The integration is expected to increase PulsePoint’s programmatic EHR reach to over 1 million National Provider Identifiers (NPIs) by November 2026.
Advertisement

OptimizeRx and PulsePoint Partner to Connect HCP Media Across the Funnel

https://www.manilatimes.net/2026/10/27/tmt-newswire/globenewswire/optimizerx-and-pulsepoint-partner-to-connect-hcp-media-across-the-funnel/2454900
OptimizeRx Corp. and PulsePoint have announced a new partnership to integrate OptimizeRx's authenticated electronic health record (EHR) and e-prescribing inventory into PulsePoint's programmatic platform. This collaboration aims to reduce fragmentation in omnichannel healthcare professional (HCP) marketing by allowing marketers to extend broader HCP campaigns into clinical workflows, making point-of-care media easier to incorporate into comprehensive media plans. The integration will expand programmatic access to EHR engagement for PulsePoint clients, bringing their programmatic EHR reach to over 1 million NPIs.

OptimizeRx and PulsePoint Partner to Connect HCP Media Across the Funnel

https://www.manilatimes.net/2026/10/27/tmt-newswire/globenewswire/optimizerx-and-pulsepoint-partner-to-connect-hcp-media-across-the-funnel/2454900/amp
OptimizeRx and PulsePoint have partnered to integrate OptimizeRx’s authenticated electronic health record (EHR) and e-prescribing inventory into PulsePoint’s programmatic platform, aiming to connect HCP media across the marketing funnel. This collaboration reduces fragmentation by allowing marketers to extend broader HCP campaigns into EHR workflows, which were historically purchased separately. The integration is expected to give PulsePoint clients access to incremental NPIs, expanding their programmatic EHR reach to over 1 million NPIs.

One manager reports sole voting power over 1.32M OptimizeRx (OPRX) shares held by clients.

https://www.stocktitan.net/sec-filings/OPRX/schedule-13g-a-optimize-rx-corp-amended-passive-investment-disclosure-df960f6f3f3d.html
Royce & Associates LP has reported a 6.98% beneficial ownership stake in OptimizeRx Corp (OPRX), totaling 1,315,057 common shares as of September 30, 2026. The firm maintains sole voting and dispositive power over these shares, which are held on behalf of its investment management clients. This disclosure was made in an amended passive investment filing (SCHEDULE 13G/A) with the SEC.

OptimizeRx stock expands access to 800,000 providers remains below its yearly high lacks? no

https://www.ad-hoc-news.de/boerse/news/corporate-news/optimizerx-stock-expands-access-to-800-000-providers-remains-below-its/70235534
OptimizeRx (OPRX) stock was trading at $8.64 on October 5, 2026, despite its OpenPath network expanding access to 800,000 healthcare professionals. The company reported a significant Q2 revenue decline of 29.8% to $20.504 million, resulting in a net loss, though gross margin remained high at 76.5%. Analysts maintain a "Moderate Buy" consensus with an average 12-month price target of $11.43, even as the stock trades substantially below its 52-week high.

Form 4 OPTIMIZERx Corp For: 2 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-optimizerx-corp-for-2-october-93CH-2720252
This article reports on a Form 4 filing for OPTIMIZERx Corp (OPRX) dated October 2, 2026. The company's stock, OPRX, was down 3.95% at the time of publication. The brief announcement provides no further details about the Form 4 filing itself.
Advertisement

Optimizerx Corp (OPRX-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/OPRX/
This page provides real-time stock price and news for Optimizerx Corp (OPRX-Q) on NASDAQ. It includes current market data, a company profile, and a list of recent news articles and analyst insights related to OptimizeRx. The company focuses on connecting patients, physicians, and pharmaceutical manufacturers to improve medication affordability and compliance.

Form 4 OPTIMIZERx Corp For: 2 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-optimizerx-corp-for-2-october-93CH-4893867
This article announces the Form 4 filing for OPTIMIZERx Corp on October 2nd. The content is brief, primarily serving as an announcement for this regulatory filing, and includes general market data and related articles from Investing.com. It highlights OPTIMIZERx Corp with its stock symbol OPRX and a recent performance of +3.16%.

Form 4 OPTIMIZERx Corp For: 2 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-optimizerx-corp-for-2-october-93CH-4864370
This article announces the filing of Form 4 for OPTIMIZERx Corp on October 2, 2026. Form 4 is a U.S. Securities and Exchange Commission filing used to disclose changes in beneficial ownership of a company's securities by insiders. The article, published by Investing.com, provides no further details beyond this announcement.

Stock vesting triggers tax withholding at OptimizeRx (OPRX): 414 shares at $8.39 each.

https://www.stocktitan.net/sec-filings/OPRX/form-4-optimize-rx-corp-insider-trading-activity-412c63d44bca.html
OptimizeRx's Chief Business Officer, Andrew J. D'Silva, had 414 shares withheld on October 1, 2026, to cover tax withholding obligations upon the vesting of restricted stock units. Each share was valued at $8.39, and his direct holdings after this transaction totaled 99,246 shares. This event is classified as a disposition of securities under Section 16 of the Securities Exchange Act.

Learn Why The Bull Case For Trade Desk Stock Could Change Following Healthcare Ad Access Expansion

https://simplywall.st/stocks/us/media/nasdaq-ttd/trade-desk/news/learn-why-the-bull-case-for-trade-desk-stock-could-change-fo
The Trade Desk (TTD) recently integrated with OptimizeRx’s OpenPath, allowing advertisers programmatic access to healthcare point-of-care inventory across 400+ EHR systems, reaching 800,000 healthcare professionals. While this offers differentiated supply, it's unlikely to immediately offset challenges like declining revenue/earnings forecasts and management changes. The article suggests this expanded access could significantly impact Trade Desk's investment narrative long-term, especially if AI acts as an additional catalyst, but near-term focus remains on stabilizing core business performance.
Advertisement

OPRX: OptimizeRx Corp Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/OPRX
This article provides a detailed overview of OptimizeRx Corp (OPRX), including its current stock price, market capitalization, and fundamental data. It highlights the company's business model as a digital health company facilitating communication between pharmaceutical companies and healthcare providers. The piece also includes recent news, such as OptimizeRx's partnership with The Trade Desk and upcoming earnings, alongside social sentiment from Stocktwits.

Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?

https://es.tradingview.com/news/zacks:a63156fa4094b:0-will-oprx-s-openpath-deal-help-ttd-capture-more-healthcare-ad-dollars/
The Trade Desk (TTD) is enhancing its presence in healthcare advertising by integrating with OptimizeRx (OPRX), providing advertisers direct access to authenticated healthcare professional inventory via TTD’s OpenPath platform. This move aims to simplify media planning for life sciences advertisers and strengthen TTD's healthcare offerings, potentially attracting new pharmaceutical clients and increasing programmatic ad spending. While TTD faces a declining stock price and higher valuation compared to peers, this partnership and other healthcare expansions could boost its competitive edge against companies like Magnite and PubMatic.

Squarepoint Ops LLC Sells 132,507 Shares of OptimizeRx Corp. $OPRX

https://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-sells-132507-shares-of-optimizerx-corp-oprx-2026-09-24/
Squarepoint Ops LLC significantly reduced its stake in OptimizeRx Corp. (NASDAQ: OPRX) by 74.6% in the second quarter, selling 132,507 shares and retaining 45,064. Despite this sale, institutional investors collectively own 76.47% of OPRX, and analysts generally maintain a "Moderate Buy" rating with a consensus price target of $11.43. OptimizeRx recently reported strong earnings, exceeding analyst expectations for both EPS and revenue.

OptimizeRx Expands Authenticated HCP Reach on The Trade Desk

https://www.martechcube.com/optimizerx-expands-authenticated-hcp-reach-on-the-trade-desk/
OptimizeRx Corp. has announced an integration with OpenPath, The Trade Desk's supply path optimization solution, to expand its authenticated HCP reach. This partnership will allow advertisers using The Trade Desk direct access to OptimizeRx’s network of over 400 EHR and e-prescribe systems, reaching 800,000 verified healthcare professionals. The integration aims to streamline the process for life sciences marketers to incorporate point-of-care inventory into their programmatic media strategies, with availability expected in Q4 2026.

Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?

https://www.tradingview.com/news/zacks:a63156fa4094b:0-will-oprx-s-openpath-deal-help-ttd-capture-more-healthcare-ad-dollars/
The Trade Desk (TTD) is enhancing its presence in healthcare advertising through a new integration with OptimizeRx (OPRX), providing advertisers direct access to authenticated healthcare professional (HCP) inventory via TTD’s OpenPath platform. This partnership aims to simplify media planning for life sciences advertisers and integrate HCP-focused campaigns with broader programmatic strategies. The deal is expected to boost TTD's healthcare offerings, complementing its existing data and measurement capabilities, and potentially attracting more pharmaceutical advertisers.
Advertisement

OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network

https://www.tradingview.com/news/stocktwits:0bdf7786d094b:0-optimizerx-partners-with-the-trade-desk-to-widen-its-healthcare-ad-network/
OptimizeRx (OPRX) has partnered with The Trade Desk (TTD) to integrate its point-of-care inventory with OpenPath, The Trade Desk’s supply path optimization solution. This integration will make OptimizeRx's healthcare ad network, which covers over 400 EHR and e-prescribe systems and reaches 800,000 healthcare professionals, directly available to advertisers through The Trade Desk’s demand-side platform. The move aims to expand programmatic access to EHR advertising, allowing advertisers to leverage existing programmatic buying infrastructure for healthcare inventory, with availability expected in Q4 2026.

OptimizeRx Corporation (OPRX) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/OPRX/
This article provides a comprehensive overview of OptimizeRx Corporation (OPRX), including its current stock price, financial performance, and historical data. It details the company's business model as a digital healthcare technology provider and offers key financial metrics, analyst insights, and comparisons to the S&P 500 benchmark. The information is presented to give investors a snapshot of OPRX's market position and operational health.

OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath

https://www.stocktitan.net/news/OPRX/optimize-rx-brings-net-new-authenticated-hcp-reach-to-the-trade-desk-zrrafy0c1tkk.html
OptimizeRx will integrate its authenticated point-of-care inventory with The Trade Desk’s OpenPath in Q4 2026, enabling advertisers to programmatically access OptimizeRx's network of over 400 EHR and e-prescribe systems. This integration will reach approximately 800,000 verified healthcare professionals, bringing in-workflow EHR placements into mainstream programmatic buying for life sciences marketers. The move aims to expand programmatic distribution for OptimizeRx, offering advertisers greater flexibility and direct access to differentiated HCP inventory.

OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath

https://www.globenewswire.com/news-release/2026/09/22/3366239/0/en/optimizerx-brings-net-new-authenticated-hcp-reach-to-the-trade-desk-through-openpath.html
OptimizeRx announced an integration with OpenPath, The Trade Desk’s supply path optimization solution, to provide advertisers direct access to OptimizeRx’s network of over 400 EHR and e-prescribe systems, reaching 800,000 verified healthcare professionals (HCPs). This integration allows life sciences marketers to incorporate OptimizeRx's point of care inventory into broader programmatic media strategies, making EHR advertising inventory more accessible and transparent. The company expects this inventory to be available through OpenPath in the fourth quarter of 2026, aiming to expand programmatic distribution for its EHR network.

OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network

https://finance.yahoo.com/healthcare/articles/optimizerx-partners-trade-desk-widen-171839653.html
OptimizeRx announced an integration with OpenPath, The Trade Desk's supply path optimization solution, to make its authenticated point-of-care inventory directly available to advertisers. This partnership expands OptimizeRx's healthcare ad network, which spans over 400 EHR and e-prescribe systems, allowing advertisers to utilize The Trade Desk's programmatic buying infrastructure for healthcare inventory. The integration aims to broaden access for life sciences advertisers and is expected to be available in Q4 2026.
Advertisement

OptimizeRx Corporation (OPRX) Stock Price & News

https://www.syfe.com/stocks/us/oprx
OptimizeRx Corporation (OPRX) is currently trading at US$9.37, up 4.93% with a market capitalization of US$145.23M. The company, founded in 2006, provides digital health messaging via electronic health records to pharmaceutical companies. Recent analyst activities include B. Riley raising and then adjusting price targets, while the company does not currently pay dividends.

OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Rating of "Moderate Buy" by Brokerages

https://www.marketbeat.com/instant-alerts/consensus-optimizerx-corp-nasdaq-oprx-given-consensus-rating-of-moderate-buy-by-brokerages-2026-09-20/
OptimizeRx Corp. (NASDAQ:OPRX) has received a consensus "Moderate Buy" rating from nine analysts, with an average 12-month price target of $11.43, significantly higher than its current share price of $7.29. The company recently surpassed quarterly earnings expectations, reporting EPS of $0.16 and revenue of $20.50 million. Institutional investors hold a substantial 76.47% stake in OptimizeRx, with several increasing their positions.

One prompt now builds patient and doctor audiences. OptimizeRx expanded the tool.

https://www.stocktitan.net/news/OPRX/optimize-rx-expands-natural-language-audience-builder-to-unify-hcp-sj1epjewh1ol.html
OptimizeRx (OPRX) has expanded its AI-powered Natural Language Audience Builder (NLAB) to allow media planners to create both claims-grade healthcare professional (HCP) and privacy-safe direct-to-consumer (DTC) audiences using a single, plain-language workflow. This upgrade integrates the company’s Micro-Neighborhood® Targeting (MNT) audiences, transforming NLAB into a platform-agnostic, no-code tool for life sciences media planning. The expansion also adds new optimization and media planning functionality specific to the DTC landscape, including interactive breakdowns of audience quality and reach, and instant generation of media channel propensities and demographic insights.

OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence

https://www.manilatimes.net/2026/09/14/tmt-newswire/globenewswire/optimizerx-expands-natural-language-audience-builder-to-unify-hcp-and-dtc-audience-intelligence/2424491/amp
OptimizeRx has expanded its AI-powered Natural Language Audience Builder (NLAB) to allow media planners to create both HCP and direct-to-consumer (DTC) audiences from a single workflow. This enhancement integrates OptimizeRx’s Micro-Neighborhood® Targeting (MNT) audiences into NLAB, enabling comprehensive life sciences media planning. The update aims to streamline audience creation, improve precision for marketing campaigns, and facilitate the activation of these audiences across various media channels.

OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence

https://finance.yahoo.com/healthcare/articles/optimizerx-expands-natural-language-audience-120000090.html
OptimizeRx has expanded its Natural Language Audience Builder (NLAB) to allow media planners to create both healthcare professional (HCP) and direct-to-consumer (DTC) audiences using a single workflow. This integration of Micro-Neighborhood® Targeting (MNT) audiences within NLAB aims to streamline media planning for life sciences companies, enabling faster and more precise audience activation. The enhancement includes new optimization features specific to the DTC landscape, such as decile-based audience quality breakdowns and instant generation of media channel propensities, ultimately helping marketers achieve higher engagement and impact.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement